I've taken a position of 1,800 shares in da super scheme.ResMed...

I've taken a position of 1,800 shares in da super scheme.

ResMed (RMD) $5.74
Short term Buy, long term Buy, volatility index Very high

Respironics, one of ResMed’s major competitors, reported
December quarter sales of US$151.9m – an increase of
29.4% assisted by revenues from acquisitions.
Respironics’ result and comments underline the strength of
the Obstructive Sleep Apnea market both in the US and
internationally. In the US, the market continues to grow at 15–
20% allowing ResMed and Fisher & Paykel Healthcare to
expand their bases. Respironics was also confident that
growth in the German market was back on track.
A number of drivers are aligning to provide ResMed with a
platform to accelerate growth over the next 12 to 18 months:
· The market in Germany is returning to growth
following the one-off impact associated with a
change in the general reimbursement structure in its
healthcare system. This is particularly important for
ResMed being its largest market outside the US and
having a higher profit margin;
· The global rollout of the AutoSet Spirit / S7 Elite
platform. This platform delivers ResMed benefits in
product offering, marketing and manufacturing;
· Adding to the tailwind has been the strengthening
Euro against the US Dollar (this outweighs a higher
AUD/USD that affects a portion of the cost base).
Action
We retain a Buy on ResMed. We reiterate that a combination
of a return to growth in the German market, the global roll-out
of the AutoSet Spirit / S7 Elite platform and the added benefit
gained from a strengthening EUR/USD will drive earnings
growth across the next 12 months.